Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned an average rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $13.60.

Several brokerages have issued reports on OBIO. Barclays dropped their price objective on Orchestra BioMed from $12.00 to $11.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Cowen started coverage on Orchestra BioMed in a report on Wednesday, December 10th. They issued a “buy” rating for the company. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th. Finally, TD Cowen began coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a “buy” rating and a $15.00 price objective on the stock.

Hedge Funds Weigh In On Orchestra BioMed

Several institutional investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Orchestra BioMed in the second quarter valued at about $31,000. Creative Planning acquired a new stake in shares of Orchestra BioMed in the second quarter valued at about $40,000. XTX Topco Ltd acquired a new position in Orchestra BioMed during the second quarter worth about $45,000. Jane Street Group LLC purchased a new position in Orchestra BioMed in the 2nd quarter valued at approximately $50,000. Finally, Bank of America Corp DE grew its holdings in Orchestra BioMed by 35.7% in the second quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock valued at $58,000 after purchasing an additional 5,678 shares during the last quarter. 53.20% of the stock is owned by institutional investors and hedge funds.

Orchestra BioMed Stock Up 7.6%

Shares of NASDAQ OBIO opened at $4.79 on Friday. The business has a 50-day moving average of $4.39 and a two-hundred day moving average of $3.42. The company has a market capitalization of $270.49 million, a price-to-earnings ratio of -2.63 and a beta of 0.63. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $6.16. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72.

Orchestra BioMed (NASDAQ:OBIO) last issued its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%.The business had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.74 million. On average, analysts forecast that Orchestra BioMed will post -1.66 earnings per share for the current fiscal year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.